ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Methylprednisolone

Also written as “methylprednisolone”, “Vasopressin; Methylprednisolone; Hydrocortisone” and “Methylprednisolone/prednisolone”.

Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Myeloma · Diabetes Insipidus · Myopathies, Structural, Congenital · Gaucher Disease, led by 9 companies.

Drug pageMethylprednisolone: every studyMany companies study it; this page follows only the 16 they lead. All 405 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 27, 200516 company-led studies, 4 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogenits history only40 open or runningphase 4since May 27, 2005May 27, 2005none ahead
Pfizerits history only40 open or runningphase 1since Dec 13, 2010Dec 13, 2010none ahead
Oncotherapeuticsits history only22 open or runningphase 1since Nov 7, 2023Nov 7, 2023Apr 1, 2027phase 1 · NCT06225310
Amsterdam Molecular Therapeuticsits history only10 open or runningphase 3since Apr 30, 2009Apr 30, 2009none ahead
Astellas Pharma11 open or runningphase 2since Jun 30, 2025Jun 30, 2025Oct 31, 2027phase 2 · NCT07052929
Bristol-Myers Squibbits history only10 open or runningphase 2since May 4, 2016May 4, 2016none ahead
Chong Kun Dang Pharmaceuticalits history only10 open or runningphase 4since Jan 3, 2019Jan 3, 2019none ahead
Eli Lillyits history only11 open or runningphase 2since May 11, 2020May 11, 2020Feb 2027phase 2 · NCT04411654
Sun Pharmaceutical Industriesits history only10 open or runningphase 2since Oct 31, 2016Oct 31, 2016none ahead

Also a collaborator on its studies: Incyte, Elan Pharmaceuticals and The Clinical Trial.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Astellas Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2025First study: phase 2 study in Myopathies, Structural, CongenitalFirst studyNCT07052929 · 9 planned · United States, Canada

Ahead

  1. Oct 31, 2027Primary completion: phase 2 study in Myopathies, Structural, CongenitalNCT07052929

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

The one study Astellas Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07052929Myopathies, Structural, Congenital · United States, Canada2RecruitingOct 31, 20279

How it is read

Names in the registry

  • “methylprednisolone”, 16 entries
  • “Methylprednisolone”, 7 entries
  • “Vasopressin; Methylprednisolone; Hydrocortisone”, 1 entry
  • “Methylprednisolone/prednisolone”, 1 entry
  • “abiraterone acetate with Methylprednisolone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.